Evidence map›Paper›PMID 28129569›Full record

ArticleInternational journal for parasitology. Drugs and drug resistance2017

Investigating the antiplasmodial activity of primary sulfonamide compounds identified in open source malaria data.

Gillian M Fisher, Silvia Bua, Sonia Del Prete, Megan S J Arnold, Clemente Capasso, Claudiu T Supuran, Katherine T Andrews, Sally-Ann Poulsen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal for parasitology. Drugs and drug resistance, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Gillian M FisherGriffith Institute for Drug Discovery, Griffith University, Queensland, Australia.
Silvia BuaNeurofarba Department, Sezione di Scienze Farmaceutiche Nutraceutiche, and Laboratorio di Chimica Bioinorganica, Università degli Studi di Firenze, Sesto Fiorentino, Florence, Italy.
Sonia Del PreteNeurofarba Department, Sezione di Scienze Farmaceutiche Nutraceutiche, and Laboratorio di Chimica Bioinorganica, Università degli Studi di Firenze, Sesto Fiorentino, Florence, Italy; Istituto di Bioscienze e Biorisorse, CNR, Via Pietro Castellino 111, Napoli, Italy.
Megan S J ArnoldGriffith Institute for Drug Discovery, Griffith University, Queensland, Australia.
Clemente CapassoIstituto di Bioscienze e Biorisorse, CNR, Via Pietro Castellino 111, Napoli, Italy.
Claudiu T SupuranNeurofarba Department, Sezione di Scienze Farmaceutiche Nutraceutiche, and Laboratorio di Chimica Bioinorganica, Università degli Studi di Firenze, Sesto Fiorentino, Florence, Italy.
Katherine T AndrewsGriffith Institute for Drug Discovery, Griffith University, Queensland, Australia. Electronic address: K.Andrews@griffith.edu.au.
Sally-Ann PoulsenGriffith Institute for Drug Discovery, Griffith University, Queensland, Australia. Electronic address: s.poulsen@griffith.edu.au.
Griffith University · AUInstitute of Biosciences and Bioresources · ITUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the past decade there has been a significant reduction in deaths due to malaria, in part due to the success of the gold standard antimalarial treatment - artemisinin combination therapies (ACTs). However the potential threat of ACT failure and the lack of a broadly effective malaria vaccine are driving efforts to discover new chemical entities (NCEs) to target this disease. The primary sulfonamide (PS) moiety is a component of several clinical drugs, including those for treatment of kidney disease, glaucoma and epilepsy, however this chemotype has not yet been exploited for malaria. In this study 31 PS compounds sourced from the GlaxoSmithKline (GSK) Tres Cantos antimalarial set (TCAMS) were investigated for their ability to selectively inhibit the in vitro growth of Plasmodium falciparum asexual stage malaria parasites. Of these, 14 compounds were found to have submicromolar activity (IC

Indexed as

AntimalarialsCarbonic Anhydrase InhibitorsCarbonic AnhydrasesHumansInhibitory Concentration 50Plasmodium falciparumPlasmodium knowlesiSulfonamidesAntimalarialsCarbonic Anhydrase InhibitorsCarbonic AnhydrasesSulfonamidesCarbonic anhydrasePlasmodium falciparumPlasmodium knowlesiPrimary sulfonamideTCAMS

Identifiers

PMID28129569
PMCPMC5271676
OpenAlexW2579472186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.